Who
Nancy Denyes
General Counsel
Company insider
Files Form 4 as: General Counsel, aTyr Pharma.
In numbers
- Trades disclosed
- 38
- Buys
- 1
- Sells
- 4
- Bought
- $9,300
- Sold
- $8,844
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 6 May 2015
- Last trade
- 4 Feb 2026
- Last filed
- 4 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Feb 2026filed 4 Feb 2026 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Sold | $1,0911,118 at $0.9761 | filing |
| 4 Feb 2026filed 4 Feb 2026 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Sold | $1,0961,118 at $0.98 | filing |
| 3 Feb 2026filed 4 Feb 2026 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Code M | —2,687 | filing |
| 3 Feb 2026filed 4 Feb 2026 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,687 at $0.00 | filing |
| 3 Feb 2026filed 4 Feb 2026 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,687 at $0.00 | filing |
| 3 Feb 2026filed 4 Feb 2026 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Code M | —2,687 | filing |
| 9 Jan 2026filed 9 Jan 2026 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —412,500 at $0.00 | filing |
| 9 Jan 2026filed 9 Jan 2026 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —412,500 at $0.00 | filing |
| 4 Feb 2025filed 4 Feb 2025 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Sold | $3,398899 at $3.78 | filing |
| 3 Feb 2025filed 4 Feb 2025 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,687 at $0.00 | filing |
| 3 Feb 2025filed 4 Feb 2025 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Code M | —2,687 | filing |
| 8 Jan 2025filed 10 Jan 2025 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —275,000 at $0.00 | filing |
| 5 Jun 2024filed 6 Jun 2024 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Bought | $9,3005,000 at $1.86 | filing |
| 5 Feb 2024filed 6 Feb 2024 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,688 at $0.00 | filing |
| 5 Feb 2024filed 6 Feb 2024 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Code M | —2,688 | filing |
| 5 Jan 2024filed 9 Jan 2024 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 16 Feb 2023filed 21 Feb 2023 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —84,023 at $0.00 | filing |
| 3 Feb 2023filed 6 Feb 2023 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,688 at $0.00 | filing |
| 3 Feb 2023filed 6 Feb 2023 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Code M | —2,688 | filing |
| 24 May 2022filed 26 May 2022 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —88,097 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.